Granted Patent
B2
US 12,478,691 · App. 17/383,138 · Granted Nov 25, 2025
Gene therapy vectors for treating heart disease
Assignee:
Tenaya Therapeutics, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure provides methods and compositions useful for the treatment or prevention of heart disease. In particular, the present disclosure provides a vector comprising a modified troponin T promoter operatively linked to a therapeutic gene product for the treatment or prevention of heart disease, e.g., cardiomyopathy. The gene product may be MYBPC3. The disclosure also provides recombinant adeno-associated virus (rAAV) virions, rAAV viral genomes, and expression cassettes and pharmaceutical compositions thereof. The disclosure further provides methods for treating a disease or disorder, such as heart disease.
Claims (6)
1 . A method of expressing full-length myosin binding protein C (MYBPC3) protein in a cell, comprising transducing the cell with a recombinant adeno-associated virus (rAAV) virion, comprising a vector genome comprising an expression cassette comprising a polynucleotide encoding the full-length MYBPC3 operatively linked to a promoter, wherein the expression cassette is flanked by a 5′ inverted terminal repeat (ITR) and a 3′ ITR; wherein the promoter is a modified human cardiac troponin T promoter consisting of between 375 bp and 425 bp; wherein the vector genome comprises at most 4.8 kbp; and wherein the full-length MYBPC3 shares at least 90% identity to the amino acid sequence of SEQ ID NO: 103, and wherein the expression cassette mediates increased expression of the MYPBC3 protein compared to an expression cassette comprising an unmodified cardiac troponin T promoter.
2 . The method of claim 1 , wherein the cell is a cardiac cell.
3 . The method of claim 1 , wherein the vector genome comprises 4.7 kbp.
4 . The method of claim 1 , wherein the promoter shares at least 95% identity to the polynucleotide sequence of SEQ ID NO: 3.
5 . The method of claim 1 , wherein the vector genome shares at least 95% identity to the polynucleotide sequence of SEQ ID NO: 102.
6 . The method of claim 1 , wherein the rAAV virion is a serotype AAV9 virion.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 23, 2021
From: LOMBARDI, LAURA
To: TENAYA THERAPEUTICS, INC.
Reel/Frame 056963/0679 →
Continuity (5)
Continuation
PCTUS2021017699
· Feb 11, 2021
Provisional Application
63047633
· Jul 2, 2020
Provisional Application
62976160
· Feb 13, 2020
References Cited (292)
US 5266488A
· Ordahl et al.
· 1993
[cited by applicant]
US 7892809B2
· Bowles et al.
· 2011
[cited by applicant]
US 8617534B2
· Sussman et al.
· 2013
[cited by applicant]
US 8632764B2
· Xiao et al.
· 2014
[cited by applicant]
US 8734809B2
· Gao et al.
· 2014
[cited by applicant]
US 8889641B2
· Asokan et al.
· 2014
[cited by applicant]
US 8933048B2
· Stelzer
· 2015
[cited by applicant]
US 9018440B2
· Yu et al.
· 2015
[cited by applicant]
US 9051387B2
· Moss et al.
· 2015
[cited by applicant]
US 9114148B2
· Hajjar et al.
· 2015
[cited by applicant]
US 9395354B2
· Sun et al.
· 2016
[cited by applicant]
US 9441244B2
· Schaffer et al.
· 2016
[cited by applicant]
US 9475845B2
· Asokan et al.
· 2016
[cited by applicant]
US 9611304B2
· Simpson et al.
· 2017
[cited by applicant]
US 9732345B2
· Martin et al.
· 2017
[cited by applicant]
US 9868937B2
· Regnier et al.
· 2018
[cited by applicant]
US 9975961B2
· Weber et al.
· 2018
[cited by applicant]
US 20030221207A1
· McMahon et al.
· 2003
[cited by applicant]
US 20040097454A1
· Reusch et al.
· 2004
[cited by applicant]
US 20090133138A1
· Tsai
· 2009
[cited by applicant]
US 20110158947A1
· Jovanovic
· 2011
[cited by applicant]
US 20110165680A1
· Blattner et al.
· 2011
[cited by applicant]
US 20130136729A1
· French et al.
· 2013
[cited by applicant]
US 20160237430A1
· Seidman et al.
· 2016
[cited by applicant]
US 20190275035A1
· Meyer et al.
· 2019
[cited by applicant]
US 20200405824A1
· Odom et al.
· 2020
[cited by applicant]
US 20220023384A1
· Pu et al.
· 2022
[cited by applicant]
US 20220273854A1
· Holzmeister et al.
· 2022
[cited by applicant]
US 20220389452A1
· Voit et al.
· 2022
[cited by applicant]
US 20230047424A1
· Voit et al.
· 2023
[cited by applicant]
US 20230372541A1
· Lombardi
· 2023
[cited by applicant]
CN 101988071A
· 2011
[cited by applicant]
CN 105378089A
· 2016
[cited by applicant]
CN 107250364A
· 2017
[cited by applicant]
CN 108384806A
· 2018
[cited by applicant]
CN 109810981A
· 2019
[cited by applicant]
DE 102011018586A1
· 2012
[cited by applicant]
EP 2792742A1
· 2014
[cited by applicant]
EP 2986712B1
· 2019
[cited by applicant]
JP 2014504871A
· 2014
[cited by applicant]
JP 2019500034A
· 2019
[cited by applicant]
JP 2020503869A
· 2020
[cited by applicant]
WO WO02081632A2
· 2002
[cited by applicant]
WO WO2008093323A2
· 2008
[cited by applicant]
WO WO2008124724A1
· 2008
[cited by applicant]
WO WO2012094560A2
· 2012
[cited by applicant]
WO WO2012162705A2
· 2012
[cited by applicant]
WO WO2013009825A1
· 2013
[cited by applicant]
WO WO2014028762A1
· 2014
[cited by examiner]
WO WO2014170470A1
· 2014
[cited by applicant]
WO WO2015124546A1
· 2015
[cited by applicant]
WO WO2015153357A1
· 2015
[cited by applicant]
WO WO2016054554A1
· 2016
[cited by applicant]
WO WO2016115543A2
· 2016
[cited by applicant]
WO WO2017091807A1
· 2017
[cited by applicant]
WO WO2017100671A1
· 2017
[cited by applicant]
WO WO2017106236A1
· 2017
[cited by applicant]
WO WO2017106313A1
· 2017
[cited by applicant]
WO WO2017192750A1
· 2017
[cited by applicant]
WO WO2017212019A1
· 2017
[cited by applicant]
WO WO2018050783A1
· 2018
[cited by applicant]
WO WO2018067701A2
· 2018
[cited by applicant]
WO WO2018129296A1
· 2018
[cited by applicant]
WO WO2018152333A1
· 2018
[cited by applicant]
WO WO2018222503A1
· 2018
[cited by applicant]
WO WO2019010301A1
· 2019
[cited by applicant]
WO WO2019028306A2
· 2019
[cited by applicant]
WO WO2019060619A1
· 2019
[cited by applicant]
WO WO2019143300A1
· 2019
[cited by applicant]
WO WO2019162356A1
· 2019
[cited by applicant]
WO WO2019183630A2
· 2019
[cited by applicant]
WO WO2020014471A1
· 2020
[cited by applicant]
WO WO2020117898A1
· 2020
[cited by applicant]
WO WO2020191300A1
· 2020
[cited by applicant]
WO WO2020198737A1
· 2020
[cited by applicant]
WO WO2021038291A1
· 2021
[cited by applicant]
WO WO2021130503A1
· 2021
[cited by applicant]
WO WO2021163357A2
· 2021
[cited by applicant]
WO WO2022011151A1
· 2022
[cited by applicant]
WO WO2022031756A1
· 2022
[cited by applicant]
WO WO2022032226A1
· 2022
[cited by applicant]
WO WO2022136655A1
· 2022
[cited by applicant]
WO WO2022175545A1
· 2022
[cited by applicant]
WO WO2022175546A1
· 2022
[cited by applicant]
WO WO2022175547A1
· 2022
[cited by applicant]
Chamberlain et al., 2016 (Geneseq Accession No. BDC71261, computer printout, pp. 1-2).
[cited by examiner]
Fotin-Mleczek et al., 2017 (Geneseq Accession No. BFB95840, computer printout, pp. 1-5).
[cited by examiner]
Bonne, G. et al., “Cardiac myosin binding protein-C gene splice acceptor site mutation is associated with familial hypertrophic cardiomyopathy,” Nature Genetics, vol. 11, pp. 438-440 (Dec. 1995).
[cited by applicant]
Buning, H. and Srivastava, A., “Capsid Modifications for Targeting and Improving the Efficacy of AAV Vectors,” Molecular Therapy Methods & Clinical Development, vol. 12, 248-265 (Mar. 2019).
[cited by applicant]
Dong, J. Y., et al., “Quantitative analysis of the packaging capacity of recombinant adeno-associated virus,” Human Gene Therapy, 7:2101-2112 (Nov. 10, 1996), 31 pages.
[cited by applicant]
Durymanov, Mikhail, et al., “Non-Viral Delivery of Nucleic Acids: Insight into Mechanisms of Overcoming Intracellular Barriers,” Frontiers in Pharmacology, vol. 9, Article 971, pp. 1-15., Aug. 2018.
[cited by applicant]
Geneseq Accession No. AXR77954, 2009, 2 pages, Bennett Seq ID 96; cited in an Office Action mailed on Dec. 3, 2021, in connection with U.S. Appl. No. 17/507,362.
[cited by applicant]
Geneseq Accession No. AXR77954, 2009, 2 pages, Bennett Seq ID 97; cited in an Office Action mailed on Dec. 3, 2021, in connection with U.S. Appl. No. 17/507,362.
[cited by applicant]
Geneseq Accession No. AXS14079, 2009, 4 pages, Katz Seq ID 102, cited in an Office Action mailed on Dec. 3, 2021, in connection with U.S. Appl. No. 17/507,362.
[cited by applicant]
Geneseq Accession No. AXS14079, 2009, 4 pages, Katz Seq ID 95; cited in an Office Action mailed on Dec. 3, 2021, in connection with U.S. Appl. No. 17/507,362.
[cited by applicant]
Geneseq Accession No. AXS14079, 2009, 5 pages. Katz Seq ID 103; cited in an Office Action mailed on Dec. 3, 2021, in connection with U.S. Appl. No. 17/507,362.
[cited by applicant]
Grieger, J. C. et al., “Packaging Capacity of Adeno-Associated Virus Serotypes: Impact of Larger Genomes on Infectivity and Postentry Steps,” Journal of Virology, Aug. 2005, vol. 79, No. 15, pp. 9933-9944, doi:10.1128/J…
[cited by applicant]
Gu, X. et al., “Cardiac functional improvement in rats with myocardial infarction by up-regulating cardiac myosin light chain kinase with neuregulin,” Cardiovascular Research (2010), vol. 88, pp. 334-343, doi:10.1093/cv…
[cited by applicant]
International Preliminary Report on Patentability for International Application No. PCT/US2021/017699, mailed on Aug. 25, 2022, 2022, 10 pages.
[cited by applicant]
International Preliminary Report on Patentability, mailed Aug. 25, 2022, for International Application No. PCT/US2021/017699 (10 total pages).
[cited by applicant]
International Search Report and Written Opinion, mailed Nov. 3, 2021, for International Application No. PCT/US2021/017699 (14 total pages).
[cited by applicant]
John Hopkins Medicine, Heath, “Cardiomyopathy,” https://www.hopkinsmedicine.org/heath/conditions-and-diseases/cardiomyopathy, retrieved from the internet Mar. 30, 2022 (4 pages).
[cited by applicant]
Kittleson, M. D. et al., “Familial Hypertrophic Cardiomyopathy in Maine Coon Cats,” Circulation, Jun. 22, 1999, 99:3172-3180.
[cited by applicant]
Lenzi et al., 2014, NCBI Bookshelf, a Service of the National Library of Medicine, National Institute of Health, Oversight and Review of Clinical Gene Transfer Protocols: Assessing the Role of the Recombinant DNA Adviso…
[cited by applicant]
Lopez-Gordo, E., et al., “AAV Vectors for Efficient Gene Delivery to Rodent Hearts,” Chapter 19, Adeno-Associated Virus Vectors: Design and Delivery, Methods in Molecular Biology, vol. 1950, pp. 311-332, https://doi.org…
[cited by applicant]
Merentie, M. et al., “Efficacy and safety of myocardial gene transfer of adenovirus, adeno-associated virus and lentivirus vectors in the mouse heart,” Gene Therapy, 23, pp. 296-305, doi:10.1038/gt.2015.114 (2016).
[cited by applicant]
Mohamed, T. M. A. et al., “Regulation of Cell Cycle to Stimulate Adult Cardiomyocyte Proliferation and Cardiac Regeneration,” Cell, vol. 173, pp. 104-116 (Mar. 2018), https://doi.org/10.1016/j.cell.2018.02.014, 26 pages.
[cited by applicant]
Mosqueira, D. et al., “CRISPR/Cas9 editing in human pluripotent stem cell-cardiomyocytes highlights arrhythmias, hypocontractility, and energy depeletion as potential therapeutic targets for hypertrophic cariomyopathy,”…
[cited by applicant]
Schlegel, P., et al., “Locally Targeted Cardiac Gene Delivery by AAV Microbubble Destruction in a Large Animal Mode,” Human Gene Therapy Methods (2016), vol. 27, No. 2, pp. 71-78, DOI: 10.1089/hgtb.2015.120 (9 total pag…
[cited by applicant]
Shim, Gayong, et al., “Nonviral Delivery Systems for Cancer Gene Therapy: Strategies and Challenges,” Current Gene Therapy, vol. 17, No. 5, pp. 1-18 (2017).
[cited by applicant]
Truong Dong-Jiunn, J., et al., “Development from an intein-mediated split-Cas9 system for gene therapy,” Nucleic Acids Research, vol. 43, No. 13, pp. 6450-6458, doi: 10.1093/nar/gkv601 (Jun. 2015).
[cited by applicant]
Watkins, H., et al., “Mutations in the cardiac myosin binding protein-C gene on chromosome 11 cause familial hypertrophic cardiomyopathy,” Nature Genetics, vol. 11, pp. 434-437 (Dec. 1995).
[cited by applicant]
Yardeni, T., et al., “Retro-orbital injections in mice,” Lab Anim (NY), 40(5): 155-160, doi:10.1038/laban0511-155 (May 2011), 17 total pages.
[cited by applicant]
U.S. Appl. No. 63/012,703, filed Apr. 20, 2020, Reid et al.
[cited by applicant]
Al, J. et al., Characterization of Recombinant Adeno-Associated Viral Transduction and Safety Profiles in Cardiomyocytes, Cell Physiol Biochem., 48(5):1894-1900 (2018) Epub Aug. 9, 2018.
[cited by applicant]
Altschul, S. F. et al., “Basic Local Alignment Search Tool,” J. Mol Biol., 215:403-410 (1990).
[cited by applicant]
Altschul, S. F. et al., “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,” Nucleic Acids Research, 25(17):3389-3402 (1997).
[cited by applicant]
Asokan, A. & Samulski, R. J., “An Emerging Adeno-Associated Viral Vector Pipeline for Cardiac Gene Therapy,” Human Gene Therapy, 24:906-913 (2013).
[cited by applicant]
Balaji, S. et al., “Pseudotyped adeno-associated viral vectors for gene transfer in dermal fibroblasts: implications for wound-healing applications,” Journal of Surgical Research, 184:691-698 (2013).
[cited by applicant]
Bardswell, S. C. et al., “Distinct Sarcomeric Substrates Are Responsible for Protein Kinase D-mediated Regulation of Cardiac Myofilament Ca2 Sensitivity and Cross-bridge Cycling,” The Journal of Biological Chemistry, 28…
[cited by applicant]
Barefield, D. Y. et al., “Experimental modeling supports a role for MyBP-HL as a novel myofilament component in arrhythmia and dilated cardiomyopathy,” Circulation, 136(16):1477-1491 (2017). doi:10.1161/CIRCULATIONAHA.1…
[cited by applicant]
Barefield, D. et al., “Haploinsufficiency of MYBPC3 Exacerbates the Development of Hypertrophic Cardiomyopathy in Heterozygous Mice,” J Mol Cell Cardiol., 79:234-243 (2015). doi:10.1016/j.yjmcc.2014.11.018.
[cited by applicant]
Behrens-Gawlik, V. et al., “MYBPC3 in hypertrophic cardiomyopathy: from mutation identification to RNA-based correction,” Pflugers Arch-Eur J Physiol, 466:215-223 (2014).
[cited by applicant]
Borgeat, K. et al., “Association of the myosin binding protein C3 mutation (MYBPC3 R820W) with cardiac death in a survey of 236 Ragdoll cats,” Journal of Veterinary Cardiology, 16:73-80 (2014).
[cited by applicant]
Borgeat, K. et al., “The influence of clinical and genetic factors on left ventricular wall thickness in Ragdoll cats,” Journal of Veterinary Cardiology, 17:S258-S267 (2015).
[cited by applicant]
Burridge, P. W. et al., “Chemically Defined Culture and Cardiomyocyte Differentiation of Human Pluripotent Stem Cells,” Curr Protoc Hum Genet., 87:21.3.1-21.3.15 (2016). doi:10.1002/0471142905.hg2103s87.
[cited by applicant]
Carrier, L. et al., “Asymmetric septal hypertrophy in heterozygous cMyBP-C null mice,” Cardiovascular Research, 63:293-304 (2004).
[cited by applicant]
Carrier, L. et al., “Cardiac myosin-binding protein C (MYBPC3) in cardiac pathophysiology,” Gene, 573:188-197 (2015).
[cited by applicant]
Carrier, L. et al., “The ubiquitin-proteasome system and nonsensemediated mRNA decay in hypertrophic cardiomyopathy,” Cardiovascular Research, 85:330-338 (2010).
[cited by applicant]
Chamberlain et al., Geneseq Accession No. BDC71261, 2016, 3 pages.
[cited by applicant]
Chen, X. et al., “Human Cardiac Troponin T Regulatory Cassettes Facilitate High-Level Transient Expression in Differentiating Skeletal Muscle and Continuous Expression in Cardiac Muscle,” Molecular Therapy, 19(1)36:S14 …
[cited by applicant]
Choi, V. W. et al., “AAV Hybrid Serotypes: Improved Vectors for Gene Delivery,” Curr Gene Ther., 5(3):299-310 (2005).
[cited by applicant]
Chu, G. & Sharp, P. A., “SV40 DNA transfection of cells in suspension: analysis of the efficiency of transcription and translation of T-antigen,” Gene, 13:197-202 (1981).
[cited by applicant]
Clark, K. R. et al., “Cell Lines for the Production of Recombinant Adeno-Associated Virus,” Human Gene Therapy, 6:1329-1341 (1995).
[cited by applicant]
Cohn, R. et al., “A Contraction Stress Model of Hypertrophic Cardiomyopathy due to Sarcomere Mutations,” Stem Cell Reports, 12:71-83 (2019).
[cited by applicant]
Colson, B. A. et al., “Site-directed spectroscopy of cardiac myosin-binding protein C reveals effects of phosphorylation on protein structural dynamics,” PNAS, 113(12):3233-3238 (2016).
[cited by applicant]
Damdindorj, L. et al., “A Comparative Analysis of Constitutive Promoters Located in Adeno-Associated Viral Vectors,” PLoS One, 9(8):e106472 (2014), 10 pages. doi:10.1371/journal.pone.0106472.
[cited by applicant]
Dhandapany, P. S. et al., “A common MYBPC3 (cardiac myosin binding protein C) variant associated with cardiomyopathies in South Asia,” Nature Genetics, 41(2):187-191 (2009).
[cited by applicant]
Freeman, L. M. et al., “Feline Hypertrophic Cardiomyopathy: A Spontaneous Large Animal Model of Human HCM,” Cariol. Res., 8(4):139-142 (2017).
[cited by applicant]
Gallo, P. et al., “A lentiviral vector with a short troponin-I promoter for tracking cardiomyocyte differentiation of human embryonic stem cells,” Gene Therapy, 15(3):161-70 (2008).
[cited by applicant]
Giles, J. et al., “Recovery of left ventricular function following in vivo reexpression of cardiac myosin binding protein C,” J. Gen. Physiol., 151(1):77-89 (2018).
[cited by applicant]
Glazier, A. A. et al., “Allelic imbalance and haploinsufficiency in MYBPC3-linked hypertrophic cardiomyopathy,” Pflügers Archiv—European Journal of Physiology, published online: Nov. 20, 2018, 13 pages. https://doi.org/…
[cited by applicant]
Glazier, A. A. et al., “HSC70 is a chaperone for wild-type and mutant cardiac myosin binding protein C,” JCI Insight. 2018; 3(11):e99319, 16 pages. https://doi.org/10.1172/jci.insight.99319.
[cited by applicant]
Graham, F. L. & Van Der EB, A. J., “A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA,” Virology, 52:456-467 (1973).
[cited by applicant]
Granström, S. et al., “Genotypeephenotype correlation between the cardiac myosin binding protein C mutation A31P and hypertrophic cardiomyopathy in a cohort of Maine Coon cats: a longitudinal study,” Journal of Veterina…
[cited by applicant]
Grunhaus, A. et al., “Association of Vaccinia Virus-Expressed Adenovirus E3-19K Glycoprotein with Class I MHC and Its Effects on Virulence in a Murine Pneumonia Model,” Virology, 200:535-546 (1994).
[cited by applicant]
Harris, S. P. et al., “Hypertrophic Cardiomyopathy in Cardiac Myosin Binding Protein-C Knockout Mice,” Circ Res., 90:594-601 (2002).
[cited by applicant]
Harris, S. P. et al., “In the Thick of It HCM-Causing Mutations in Myosin Binding Proteins of the Thick Filament,” Circ Res., 108:751-764 (2011).
[cited by applicant]
Helms, A. S. et al., “Effects of MYBPC3 loss of function mutations preceding hypertrophic cardiomyopathy,” JCI Insight, Published Dec. 26, 2019, 42 pages. https://doi.org/10.1172/jci.insight.133782.
[cited by applicant]
Helms, A. S. et al., “Effects of MYBPC3 loss-of-function mutations preceding hypertrophic cardiomyopathy,” JCI Insight, 5(2):e133782 (2020), 20 pages. https://doi.org/10.1172/jci.insight.133782.
[cited by applicant]
Helms, A. S. et al., “Sarcomere Mutation-Specific Expression Patterns in Human Hypertrophic Cardiomyopathy,” Circ Cardiovasc Genet., 7:434-443 (2014).
[cited by applicant]
Irion, S. et al., “Identification and targeting of the ROSA26 locus in human embryonic stem cells,” Nature Biotechnology, 25(12):1477-1482 (2007).
[cited by applicant]
Jaski, B. E. et al., “Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID Trial), a First-in-Human Phase 1/2 Clinical Trial,” J Card Fail., 15(3):171-181 (2009). doi:10.1016/j.c…
[cited by applicant]
Katz, M. G. et al., “Gene delivery technologies for cardiac applications,” Gene Ther., 19(6):659-669 (2012). doi:10.1038/gt.2012.11.
[cited by applicant]
Katz et al., Geneseq Accession No. AXS14079, 2009, 4 pages.
[cited by applicant]
Keaveney et al., GenEMBL Accession No. MH458079, 2018, 2 pages.
[cited by applicant]
Kittleson, M. D. et al., “The genetic basis of hypertrophic cardiomyopathy in cats and humans,” Journal of Veterinary Cardiology, 17:S53-S73 (2015).
[cited by applicant]
Konkalmatt, P. R. et al., “Cardiac-Selective Expression of EcSOD After Systemic Injection of AAV9 Protects the Heart Against Post-MI LV Remodeling,” Circ Cardiovasc Imaging, 6(3):478-486 (2013). doi:10.1161/CIRCIMAGING.…
[cited by applicant]
Kotterman, M. A. & Schaffer, D. V., “Engineering adeno-associated viruses for clinical gene therapy,” Nature Reviews Genetics, 15:445-451 (2014).
[cited by applicant]
Lekanne Deprez, R. H. et al., “Two cases of severe neonatal hypertrophic cardiomyopathy caused by compound heterozygous mutations in the MYBPC3 gene,” J Med Genet, 43:829-832 (2006). doi:10.1136/jmg.2005.040329.
[cited by applicant]
Li, J. et al., “AAV9 gene transfer of cMyBPC N-terminal domains ameliorates cardiomyopathy in cMyBPC-deficient mice,” JCI Insight, 5(17):e130182 (2020), 19 pages. https://doi.org/10.1172/jci.insight.130182.
[cited by applicant]
Lian, X. et al., “Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling,” PNAS, Published online May 29, 2012, 109(27):E1848-E1857. https://doi.org/10.…
[cited by applicant]
Liu, Y. et al., “Generation of Targeted Adeno-Associated Virus (AAV) Vectors for Human Gene Therapy,” Current Pharmaceutical Design, 21:3248-3256 (2015).
[cited by applicant]
Liu, X. et al., “Screening Mutations of MYBPC3 in 114 Unrelated Patients with Hypertrophic Cardiomyopathy by Targeted Capture and Nextgeneration Sequencing,” Scientific Reports, 5:11411 (2015), 8 pages. doi:10.1038/srep…
[cited by applicant]
Longerie, M. et al., “
[cited by applicant]
Ma, H. et al., “Cell-specific expression of SERCA, the exogenous Ca2+ transport ATPase, in cardiac myocytes,” Am J Physiol Cell Physiol, 286:C556-C564 (2004). First published Oct. 30, 2003. 10.1152/ajpcell.00328.2003.
[cited by applicant]
Ma, Z. et al., “Contractile deficits in engineered cardiac microtissues as a result of MYBPC3 deficiency and mechanical overload,” Nat Biomed Eng, 2:955-967 (2018). https://doi.org/10.1038/s41551-018-0280-4, and Supplem…
[cited by applicant]
Mamidi, R. et al., “Cardiac myosin binding protein-C: a novel sarcomeric target for gene therapy,” Pflugers Arch—Eur J Physiol, 466:225-230 (2014).
[cited by applicant]
Marian, A. J. & Braunwald, E., “Hypertrophic Cardiomyopathy Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy,” Circ Res., 121:749-770 (2017). doi: 10.1161/CIRCRESAHA.117.311059.
[cited by applicant]
Maron, B. J., “Clinical Course and Management of Hypertrophic Cardiomyopathy,” N Engl J Med, 379:655-668 (2018).
[cited by applicant]
Marston, S. et al., “Evidence From Human Myectomy Samples That MYBPC3 Mutations Cause Hypertrophic Cardiomyopathy Through Haploinsufficiency,” Circ Res., 105:219-222 (2009).
[cited by applicant]
Marziliano, N. et al., “A Case of Compound Mutations in the MYBPC3 Gene Associated with Biventricular Hypertrophy and Neonatal Death,” Neonatology, 102:254-258 (2012).
[cited by applicant]
McConnell, B. K. et al., “Dilated cardiomyopathy in homozygous myosin-binding protein-C mutant mice,” J Clin Invest., 104(9):1235-1244 (1999).
[cited by applicant]
McNamara, J. W. et al., “Ablation of cardiac myosin binding protein-C disrupts the super-relaxed state of myosin in murine cardiomyocytes,” J Mol Cell Cardiol., 94:65-71 (2016). doi:10.1016/j.yjmcc.2016.03.009.
[cited by applicant]
McNamara, J. W. et al., “MYBPC3 mutations are associated with a reduced super-relaxed state in patients with hypertrophic cardiomyopathy,” PLoS One, 12(6):e0180064 (2017), 22 pages. https://doi.org/10.1371/journal.pone.…
[cited by applicant]
Mearini, G. et al., “Mybpc3 gene therapy for neonatal cardiomyopathy enables long-term disease prevention in mice,” Nature Communications, 5:5155 (2014), doi: 10.1038/ncomms6515, 10 pages. http://www.nature.com/natureco…
[cited by applicant]
Mearini, G. et al., “Repair of Mybpc3 mRNA by 5′-trans-splicing in a Mouse Model of Hypertrophic Cardiomyopathy,” Molecular Therapy Nucleic Acids, Jul. 2, 2013;2(7):e102. doi: 10.1038/mtna.2013.31, 9 pages.
[cited by applicant]
Merkulov, S. et al., “In Vivo Cardiac Myosin Binding Protein C Gene Transfer Rescues Myofilament Contractile Dysfunction in Cardiac Myosin Binding Protein C Null Mice,” Circ Heart Fail., 5(5):635-644 (2012).
[cited by applicant]
Meurs, K. M. et al., “A substitution mutation in the myosin binding protein C gene in ragdoll hypertrophic cardiomyopathy,” Genomics, 90:261-264 (2007).
[cited by applicant]
Meurs, K. M. et al., “A cardiac myosin binding protein C mutation in the Maine Coon cat with familial hypertrophic cardiomyopathy,” Human Molecular Genetics, 14(23):0 3587-3593 (2005).
[cited by applicant]
Miller, A. D., “Human gene therapy comes of age,” Nature, 357:455-460 (1992).
[cited by applicant]
Moolman, J. A. et al., “A Newly Created Splice Donor Site in Exon 25 of the MyBP-C Gene Is Responsible for Inherited Hypertrophic Cardiomyopathy With Incomplete Disease Penetrance,” Circulation, 101:1396-1402 (2000).
[cited by applicant]
Moss, R. L., “Cardiacmyosin-binding protein C: A protein once at loose ends finds its regulatory groove,” PNAS, 113(12):3133-3135 (2016).
[cited by applicant]
Najafi, A. et al., “Sexual dimorphic response to exercise in hypertrophic cardiomyopathy-associated MYBPC3-targeted knock-in mice,” Pflugers Arch—Eur J Physiol, 467:1303-1317 (2015).
[cited by applicant]
Naso, M. F. et al., “Adeno-Associated Virus (AAV) as a Vector for Gene Therapy,” BioDrugs, 31:317-334 (2017).
[cited by applicant]
Needleman, S. B. & Wunsch, C. D., “A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins,” J. Mol. Biol., 48:443-453 (1970).
[cited by applicant]
O'Leary, T. S. et al., “MYBPC3 truncation mutations enhance actomyosin contractile mechanics in human hypertrophic cardiomyopathy,” J Mol Cell Cardiol., 127:165-173 (2019). doi:10.1016/j.yjmcc.2018.12.003.
[cited by applicant]
Pearson, W. R. & Lipman, D. J., “Improved tools for biological sequence comparison,” Proc. Natl. Acad. Sci., 85:2444-2448 (1988).
[cited by applicant]
Pellegrino, A. et al., “Assessment of regional left ventricular systolic function by strain imaging echocardiography in phenotypically normal and abnormal Maine coon cats tested for the A31P mutation in the MYBPC3 gene,…
[cited by applicant]
Phillips, M. I. et al., “Vigilant Vector: Heart-Specific Promoter in an Adeno-Associated Virus Vector for Cardioprotection,” Hypertension, 39[part2]:651-655 (2002).
[cited by applicant]
Piras, B. A. et al., “Systemic injection of AAV9 carrying a periostin promoter targets gene expression to a myofibroblast-like lineage in mouse hearts after reperfused myocardial infarction,” Gene Therapy, 23:469-478 (2…
[cited by applicant]
Pozsgai, E. R. et al., “Systemic AAV-Mediated b-Sarcoglycan Delivery Targeting Cardiac and Skeletal Muscle Ameliorates Histological and Functional Deficits in LGMD2E Mice,” Molecular Therapy, 24(4):855-869 (2017).
[cited by applicant]
Prasad, K. -M. et al., “Robust Cardiomyocyte-Specific Gene Expression Following Systemic Injection of AAV: In Vivo Gene Delivery Follows a Poisson Distribution,” Gene Ther., 18(1):43-52 (2011). doi:10.1038/gt.2010.105.
[cited by applicant]
Previs, M. J. et al., “Molecular Mechanics of Cardiac Myosin Binding Protein-C in Native Thick Filaments,” Science, 337(6099):1215-1218 (2012). doi:10.1126/science.1223602.
[cited by applicant]
Prondzynski, M. et al., “Evaluation of MYBPC3 trans-Splicing and Gene Replacement as Therapeutic Options in Human iPSC-Derived Cardiomyocytes,” Molecular Therapy: Nucleic Acids, 7:475-486 (2017).
[cited by applicant]
Prondzynski, M. et al., “Gene therapy strategies in the treatment of hypertrophic cardiomyopathy,” Pflügers Archiv—European Journal of Physiology, 471(6244), 9 pages (2018). doi:10.1007/s00424-018-2173-5.
[cited by applicant]
Rosas, P. C. et al., “Phosphorylation of Cardiac Myosin Binding Protein-C is a Critical Mediator of Diastolic Function,” Circ Heart Fail., 8(3):582-594 (2015).
[cited by applicant]
Rottbauer, W. et al., “Novel splice donor site mutation in the cardiac myosin-binding protein-C gene in familial hypertrophic cardiomyopathy. Characterization of cardiac transcript and protein,” J Clin Invest., 100(2):4…
[cited by applicant]
Sadayappan, S. & De Tombe, P. P., “Cardiac myosin binding protein-C: redefining its structure and function,” Biophys Rev, 4:93-106 (2012).
[cited by applicant]
Schlossarek, S. et al., “Defective proteolytic systems in Mybpc3-targeted mice with cardiac hypertrophy,” Basic Res Cardiol, 107:235 (2012), 13 pages. doi: 10.1007/s00395-011-0235-3.
[cited by applicant]
Stern, J. A. et al., “A Small Molecule Inhibitor of Sarcomere Contractility Acutely Relieves Left Ventricular Outflow Tract Obstruction in Feline Hypertrophic Cardiomyopathy,” PLoS One, 11(12): e0168407, 13 pages. doi:1…
[cited by applicant]
Strausberg et al., GenEMBL Accession No. BC136543, 2008, 7 pages.
[cited by applicant]
Tidyman, W. E. et al., “In vivo regulation of the chicken cardiac troponin T gene promoter in zebrafish embryos,” Developmental Dynamics, 227:484-496 (2003).
[cited by applicant]
Toepfer, C. N. et al., “Hypertrophic cardiomyopathy mutations in MYBPC3 dysregulate myosin,” Sci. Transl. Med., 11:eaat1199 (2019), 10 pages. doi: 10.1126/scitranslmed.aat1199.
[cited by applicant]
Tohyama, S. et al., “Distinct Metabolic Flow Enables Large-Scale Purification of Mouse and Human Pluripotent Stem Cell-Derived Cardiomyocytes,” Cell Stem Cell, 12(1):127-37 (2013).
[cited by applicant]
Van Dijk, S. J. et al., “Cardiac Myosin-Binding Protein C Mutations and Hypertrophic Cardiomyopathy,” Circulation, 119:1473-1483 (2009).
[cited by applicant]
Van Dijk, S. J. et al., “Contractile Dysfunction Irrespective of the Mutant Protein in Human Hypertrophic Cardiomyopathy With Normal Systolic Function,” Circ Heart Fail., 5:36-46 (2012).
[cited by applicant]
Van Dijk, S. J. et al., “Point mutations in the tri-helix bundle of the M-domain of cardiac myosin binding protein-C influence systolic duration and delay cardiac relaxation,” J Mol Cell Cardiol., 119:116-124 (2018). do…
[cited by applicant]
Van Dijk, S. J. et al., “The A31P missense mutation in cardiac myosin binding protein C alters protein structure but does not cause haploinsufficiency,” Arch Biochem Biophys., 601:133-140 (2016). doi:10.1016/j.abb.2016.…
[cited by applicant]
Vera, T. R. et al., “The R820W mutation in the MYBPC3 gene, associated with hypertrophic cardiomyopathy in cats, causes hypertrophic cardiomyopathy and left ventricular non-compaction in humans,” Int J Cardiol, 145(2):4…
[cited by applicant]
Vignier, N. et al., “Nonsense-Mediated mRNA Decay and Ubiquitin-Proteasome System Regulate Cardiac Myosin-Binding Protein C Mutant Levels in Cardiomyopathie Mice,” Circ Res., 105:239-248 (2009).
[cited by applicant]
Walsh, R. et al., “Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples,” Genetics in Medicine, 19(2):192-203 (2017).
[cited by applicant]
Werfel, S. et al., “Rapid and highly efficient inducible cardiac gene knockout in adult mice using AAV-mediated expression of Cre recombinase,” Cardiovascular Research, 104(1):15-23 ( 2014).
[cited by applicant]
Wess, G. et al., “Association of A31P and A74T Polymorphisms in the Myosin Binding Protein C3 Gene and Hypertrophic Cardiomyopathy in Maine Coon and Other Breed Cats,” J Vet Intern Med, 24:527-532 (2010).
[cited by applicant]
Wessels, M. W. et al., “Compound heterozygous or homozygous truncating MYBPC3 mutations cause lethal cardiomyopathy with features of noncompaction and septal defects,” European Journal of Human Genetics, 23:922-928 (201…
[cited by applicant]
Wijnker, P. J. M. et al., “Comparison of the effects of a truncating and a missense MYBPC3 mutation on contractile parameters of engineered heart tissue,” Journal of Molecular and Cellular Cardiology, 97:82-92 (2016).
[cited by applicant]
Wu, Z. et al., “Effect of Genome Size on AAV Vector Packaging,” Molecular Therapy, 18:80-86 (2010).
[cited by applicant]
Xin, B. et al., “Homozygosity for a Novel Splice Site Mutation in the Cardiac Myosin-Binding Protein C Gene Causes Severe Neonatal Hypertrophic Cardiomyopathy,” American Journal of Medical Genetics Part A, 143A:2662-266…
[cited by applicant]
Yang, Q. et al., “A mouse model of myosin binding protein C human familial hypertrophic cardiomyopathy,” J Clin Invest., 102(7):1292-1300 (1998). https://doi.org/10.1172/JCI3880.
[cited by applicant]
Zahka, K. et al., “Homozygous mutation of MYBPC3 associated with severe infantile hypertrophic cardiomyopathy at high frequency among the Amish,” Heart, 94:1326-1330 (2008).
[cited by applicant]
Zincarelli, C. et al., “Analysis of AAV Serotypes 1-9 Mediated Gene Expression and Tropism in Mice After Systemic Injection,” Molecular Therapy, 16(6):1073-1080 (2008).
[cited by applicant]
Carrier, L., et al., “Organization and Sequence of Human Cardiac Myosin Binding Protein C Gene (MYBPC3) and Identification of Mutations Predicted to Produce Truncated Proteins in Familial Hypertrophic Cardiomyopathy,” C…
[cited by applicant]
Chamberlain, K., et al., “Cardiac gene therapy with adeno-associated virus-based vectors,” Current Opinion in Cardiology 2017, vol. 32, pp. 275-282, DOI:10.1097/HCO.0000000000000386.
[cited by applicant]
Chute, J. P., “Stem cell homing,” Current Opinion in Hematology 2006, vol. 13, pp. 399-406.
[cited by applicant]
Cooper, T. A. and Ordahl, C. P., “A Single Cardiac Troponin T Gene Generates Embryonic and Adult Isoforms via Developmentally Regulated Alternate Splicing,” The Journal of Biological Chemistry, 1985, vol. 260, No. 20, I…
[cited by applicant]
Dong, B., et al., “Characterization of Genome Integrity for Oversized Recombinant AAV Vector,” Molecular Therapy, Jan. 2010, vol. 18, No. 1, pp. 87-92, published online Nov. 10, 2009, DOI: 10.1038/mt.2009.258.
[cited by applicant]
Final Office Action, mailed Mar. 21, 2022, for U.S. Appl. No. 17/507,362 (12 pages).
[cited by applicant]
Final Rejection Office Action for U.S. Appl. No. 17/581,576, mailed on Nov. 4, 2022, 10 pages.
[cited by applicant]
Foust, K. D., et al., “Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN,” Nature Biotechnology, vol. 28, No. 3, Mar. 2010, pp. 271-274, including Online Methods, 2 page…
[cited by applicant]
Galinska-Rakoczy, A. et al., “Structural Basis for the Regulation of Muscle Contraction by Troponin and Tropomyosin,” J. Mol. Biol. 2008, vol. 379, pp. 929-935, doi:10.1016/j.jmb.2008.04.062.
[cited by applicant]
Hannah-Shmouni, F., et al., “The Genetic Challenges and Opportunities in Advanced Heart Failure,” Canadian Journal of Cardiology 2015, vol. 31, pp. 1338-1350, http://dx.doi.org/10.1016/j.cjca.2015.07.735.
[cited by applicant]
Harlan, S. M., et al., “Requirement of TCTG (G/C) Direct Repeats and Overlapping GATA Site for Maintaining the Cardiac-Specific Expression of Cardiac troponin T in Developing and Adult Mice,” The Anatomical Record 2008,…
[cited by applicant]
Iannello, R. C., et al., “Characterization of a Promoter Element Required for Transcription in Myocardial Cells,” The Journal of Biological Chemistry 1991, vol. 266, No. 5, Issue of Feb. 15, pp. 3309-3316.
[cited by applicant]
Khajetoorians, D., et al., “Replacement of Mybpc3 Mutation by 5′-trans-splicing in a Knock-in Mouse Model: A Step Towards Casual Therapy of Hypertrophic Cardiomyopathy,” Circulation Research, vol. 111, No. 12, Dec. 7, 2…
[cited by applicant]
Knöll, R., “Myosin binding protein C: implications for signal-transduction,” Journal of Muscle Research and Cell Motility 2012, vol. 33, pp. 31-42, published online Dec. 16, 2011, DOI: 10.1007/S10974-011-9281-6.
[cited by applicant]
Li, L. et al., “Effects of administration route on migration and distribution of neural progenitor cells transplanted into rats with focal cerebral ischemia, an MRI study,” Journal of Cerebral Blood Flow and Metabolism …
[cited by applicant]
Lombardi, L., et al., Reversal of Cardiac Hypertrophy with an Optimized MYBPC3 Gene Therapy, 2021 American Society of Gene & Cell Therapy 24th Annual Meeting, Apr. 27, 2021, 1 page.
[cited by applicant]
Lombardi, L. M., et al., Prevention of Premature Lethality and Reversal of Cardiac Hypertrophy with an Optimized MYBPC3 Gene Therapy, 2021 Congress of the European Society of Gene and Cell Therapy, Oct. 20, 2021, 1 page.
[cited by applicant]
Lyon, A. R., et al., “Gene therapy: targeting the myocardium,” Heart 2008, 94:89-99; doi:10.1136/hrt.2007.116483.
[cited by applicant]
Mar, J. H., et al., “A conserved CATTCCT motif is required for skeletal muscle-specific activity of the cardiac troponin T gene promoter,” Proc. Natl. Acad. Sci., vol. 85, pp. 6404-6408, Sep. 1988.
[cited by applicant]
Mar, J. H., et al., “Analysis of the Upstream Regions Governing Expression of the Chicken Cardiac Troponin T Gene in Embryonic Cardiac Skeletal Muscle Cells,” The Journal of Cell Biology, vol. 107, Aug. 1988, pp. 573-58…
[cited by applicant]
Marian, A. J., “Hypertrophic cardiomyopathy: from genetics to treatment,” European Journal of Clinical Investigation, vol. 40, pp. 360-369, Mar. 17, 2010. DOI: 10.1111/j.1365-2362.2010.02268.x.
[cited by applicant]
Non-Final Office Action, mailed Apr. 26, 2022, for U.S. Appl. No. 17/581,576 (24 pages).
[cited by applicant]
Non-Final Office Action mailed Dec. 3, 2021 for U.S. Appl. No. 17/507,362, 27 pages.
[cited by applicant]
Non-Final Office Action mailed May 25, 2021 for U.S. Appl. No. 17/210,882, 21 pages.
[cited by applicant]
Parr et al., “Bone marrow-derived mesenchymal stromal cells for the repair of central nervous system injury,” Bone Marrow Transplantation 2007, vol. 40, pp. 609-619, doi:10.1038/sj.bmt.1705757; published online Jul. 2, …
[cited by applicant]
Prasad, K.-M., et al., “A single direct injection into the left ventricular wall of an adeno-associated virus 9 (AAV9) vector expressing extracellular superoxide dismutase from the cardiac troponin-T promoter protects m…
[cited by applicant]
Restriction Requirement for U.S. Appl. No. 18/361,571 dated Oct. 16, 2023, 8 pages.
[cited by applicant]
Seidman, C. E., et al., “Identifying Sarcomere Gene Mutations in Hypertrophic Cardiomyopathy,” Circulation Research, Mar. 18, 2011, pp. 743-750, DOI: 10.1161/CIRCRESAHA.110.223834.
[cited by applicant]
Tsui, J. H., et al., “Modeling Hypertrophic Cardiomyopathy Due to MYBPC3 Haploinsufficiency with Engineered Heart Tissues,” Heart Development and Disease: From Genes to Cures—2023 Keystone Symposia Event, Feb. 12, 2023,…
[cited by applicant]
Wu, Z., et al., “Optimization of Self-complementary AAV Vectors for Liver-directed Expression Results in Sustained Correction of Hemophilia B at Low Vector Dose,” Mol. Therapy, Feb. 2008, vol. 16, No. 2, pp. 280-289, pu…
[cited by applicant]
Geneseq Accession No. AXS14079, 2009, 4 pages, Katz Seq ID 335, cited in an Office Action mailed on Dec. 3, 2021, in connection with U.S. Appl. No. 17/507,362.
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 18/361,571 dated Dec. 27, 2023, 21 pages.
[cited by applicant]
Final Office Action for U.S. Appl. No. 18/361,571 dated Apr. 12, 2024, 11 pages.
[cited by applicant]
Grieger, J.C., et al., “Production and characterization of adeno-associated viral vectors,” Nature Protocols, 2006, vol. 1(3), pp. 1412-1428.
[cited by applicant]
Kaya, et al., “Comparison of IL-10 and MCP-1-7ND gene transfer with AAV9 vectors for protection from murine autoimmune myocarditis,” Cardiovasc Res. Jul. 1, 2011; 91(1):116-23. Epub Feb. 25, 2011.
[cited by applicant]
NCBI Reference Sequence: NG_007556.1: “
[cited by applicant]
NCBI Reference Sequence: NM_000256.2: “
[cited by applicant]
NCBI Reference Sequence: NP_000247.2: “Myosin-binding protein C, cardiac-type [
[cited by applicant]
Non-Final Office Action for U.S. Appl. No. 18/361,571 mailed Sep. 5, 2024, 34 pages.
[cited by applicant]
Fong, et al., “Modeling the Evolutionary Architectures of Transcribed Human Enhancer Sequences Reveals Distinct Origins, Functions, and Associations with Human Trait Variation,” Mol Biol Evol. Aug. 23, 2021; 38(9):3681-…
[cited by applicant]
Panigrahi, et al., “Mechanisms of enhancer action: the known and the unknown,” Genome Biol. Apr. 15, 2021; 22(1):108, 30 pages.
[cited by applicant]
Final Office Action for U.S. Appl. No. 18/361,571 mailed Mar. 11, 2025, 26 pages.
[cited by applicant]
Levitt, et al., “Definition of an efficient synthetic poly(A) site,” Genes Dev. Jul. 1989; 3(7):1019-25.
[cited by applicant]